Jacobs Levy Equity Management Inc. Has $1.47 Million Stock Position in Enanta Pharmaceuticals, Inc. $ENTA

Jacobs Levy Equity Management Inc. lowered its stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 8.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 266,768 shares of the biotechnology company’s stock after selling 23,243 shares during the period. Jacobs Levy Equity Management Inc.’s holdings in Enanta Pharmaceuticals were worth $1,473,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently made changes to their positions in ENTA. Dimensional Fund Advisors LP raised its holdings in shares of Enanta Pharmaceuticals by 52.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 297,106 shares of the biotechnology company’s stock valued at $1,708,000 after purchasing an additional 102,646 shares during the period. Jane Street Group LLC raised its holdings in shares of Enanta Pharmaceuticals by 34.1% in the 4th quarter. Jane Street Group LLC now owns 31,072 shares of the biotechnology company’s stock worth $179,000 after acquiring an additional 7,896 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in shares of Enanta Pharmaceuticals by 100.8% in the 4th quarter. BNP Paribas Financial Markets now owns 71,104 shares of the biotechnology company’s stock worth $409,000 after acquiring an additional 35,695 shares during the last quarter. Millennium Management LLC raised its holdings in shares of Enanta Pharmaceuticals by 22.7% in the 4th quarter. Millennium Management LLC now owns 896,987 shares of the biotechnology company’s stock worth $5,158,000 after acquiring an additional 165,692 shares during the last quarter. Finally, Sherbrooke Park Advisers LLC acquired a new stake in shares of Enanta Pharmaceuticals in the 4th quarter worth about $192,000. Institutional investors and hedge funds own 94.99% of the company’s stock.

Wall Street Analysts Forecast Growth

ENTA has been the topic of a number of analyst reports. Westpark Capital initiated coverage on shares of Enanta Pharmaceuticals in a report on Tuesday, September 2nd. They issued a “buy” rating and a $24.00 target price on the stock. HC Wainwright initiated coverage on shares of Enanta Pharmaceuticals in a report on Monday, July 28th. They issued a “buy” rating and a $20.00 target price on the stock. Wall Street Zen upgraded shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, June 22nd. Finally, JMP Securities upped their target price on shares of Enanta Pharmaceuticals from $24.00 to $25.00 and gave the stock a “market outperform” rating in a report on Tuesday, August 12th. Four analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Enanta Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $22.25.

Enanta Pharmaceuticals Stock Performance

NASDAQ:ENTA opened at $8.66 on Friday. The firm has a market cap of $185.15 million, a price-to-earnings ratio of -2.00 and a beta of 0.84. Enanta Pharmaceuticals, Inc. has a 52 week low of $4.09 and a 52 week high of $13.37. The firm has a 50-day moving average price of $7.85 and a two-hundred day moving average price of $6.80.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its earnings results on Monday, August 11th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.25) by $0.40. Enanta Pharmaceuticals had a negative net margin of 141.98% and a negative return on equity of 89.02%. The firm had revenue of $18.31 million during the quarter, compared to the consensus estimate of $16.21 million. As a group, sell-side analysts forecast that Enanta Pharmaceuticals, Inc. will post -4.65 earnings per share for the current year.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.